Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin

AIDS. 1993 Sep;7(9):1181-4. doi: 10.1097/00002030-199309000-00005.

Abstract

Objective: To determine whether synergistic inhibition of HIV-1 replication would result from the in vitro use of nevirapine in combination with zidovudine, interferon (IFN)-alpha 2C, and CD4 immunoadhesin.

Design and methods: The non-nucleoside reverse transcriptase inhibitor nevirapine (formerly BI-RG-587) was tested in combination with the other antiretrovial agents. Assays were performed on stimulated peripheral blood lymphocytes infected with HIV-1. Virus replication was assessed by the release of viral p24 antigen into culture supernatants. The median-effect principle was used to assess for synergistic interactions of the combined agents.

Results: Zidovudine, IFN-alpha 2C and CD4 immunoadhesin, when used in combination with nevirapine, synergistically inhibited HIV-1 replication in human peripheral blood lymphocytes compared with each agent used alone. Some analyses were also consistent with additive effects, but antagonism was not noted.

Conclusion: These in vitro findings provide a scientific basis for future trials with similar drug combinations.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antiviral Agents / pharmacology
  • CD4 Immunoadhesins / pharmacology*
  • Drug Synergism
  • Feasibility Studies
  • HIV Reverse Transcriptase
  • HIV-1 / drug effects*
  • HIV-1 / physiology
  • Humans
  • In Vitro Techniques
  • Interferon Type I / pharmacology*
  • Nevirapine
  • Pyridines / pharmacology*
  • Recombinant Proteins
  • Reverse Transcriptase Inhibitors
  • Virus Replication / drug effects
  • Zidovudine / pharmacology*

Substances

  • Antiviral Agents
  • CD4 Immunoadhesins
  • Interferon Type I
  • Pyridines
  • Recombinant Proteins
  • Reverse Transcriptase Inhibitors
  • Zidovudine
  • Nevirapine
  • HIV Reverse Transcriptase